Summit Therapeutics Share Discussion Threads

[chrisatrdg] 25/2/2017 13:00

Per share option RNS this week reported on as follows - more exposure for Summit:




X proactive X investors

[hugus maximus] 24/2/2017 17:27

MM's must be up to fun and games unless some sells are buys ... 120,000 sells toward the later afternoon with no mid price change? (against a total of 12,000 bought all day?)

I guess it's impossible to rely on the reported buys and sells?

[luminoso] 24/2/2017 16:45

Sort of implies its a potential cure, but maybe its just suggesting that the developing science of utrophin upregulation might lead to the same result for dystrophin one day. May seem like semantics but when we discuss potential competitors, the notions of 'cure', 'treatment', and 'palliative' come into play IMO.

[solomon] 24/2/2017 15:54

I also struggle with "rectify the underlying cause of DMD". But the text does state "an exciting development in the quest for a cure." So it's not saying "cure"

[luminoso] 24/2/2017 15:47

Not sure about the article's reference to a potential 'cure'. Surely a Cure would be something that gets the body to operate normally, ie produce dystrophin. I have always seen EZD as a 'treatment' and potentially a very effective one at that, but not as a potential 'cure'. Perhaps I am wrong and someone more technical can advise.

[waterloo01] 24/2/2017 13:17

We also get a mention further down

Since then DMD has attracted a lot of attention. Other companies operating in the area have seen their share prices soar as investors speculate that they too will benefit from drug approval without the need for a positive clinical trial result. One of those is the UK’s Summit Therapeutics, which is now working in collaboration with Sarepta to bring its drug, Ezutromid, to market. Ezutromid not only has the potential to treat 100 per cent of DMD patients – Exondys only works for 13 per cent – but has the potential to rectify the underlying cause of DMD, an exciting development in the quest for a cure.

[football] 24/2/2017 13:09

read more here

But big pharma remains uninspiring. Not since Eli Lilly discovered daptomycin in 1984 has the industry come up with a completely novel antibiotic. During that time, all but a few big pharma companies have shuttered their bacterial research units and in 2016 AstraZeneca became the latest company to pull out of anti-bacterial drug development when it sold its antibiotics business to Pfizer. GlaxoSmithKline (GSK)is one of the few big players that’s kept at it, sinking about $1bn into anti-bacterial research over the past decade, but to little avail. Progress at smaller companies has also been negligible. Motif Bio (MTFB) - which owns a novel antibiotic called iclaprim – has faced major funding difficulties, causing a delay in late-stage clinical trials. Redx Pharma (REDX) and Summit Therapeutics (SUMM)

have antibiotics in the early stage of development, but both companies also have other projects in more exciting areas of medicine: investment in antibiotics has rather taken a back seat.

[waterloo01] 24/2/2017 08:35

Cheers FD, Daffs up here in the South!

Chris, it's highly likely that the final sites won't open. Most companies get more centres involved than needed. We do know that they have more boys willing and signed up than needed, so any 'bottle neck' will be in each sites ability to handle patients.

Patient last dose RNS could drop anytime.

[freedosh] 24/2/2017 00:32

"Masking" has the same meaning as "blinding"/"blinded"
So "no masking" = "open label" study
I.e investigators including the company can see what the patient is receiving.
GLA from sunny and v hot Perth WA. Will be home st the first sign of Spring.

[chrisatrdg] 23/2/2017 21:20

Thanks waterloo01 for looking at the gmcc posting as clearly there were a number of changes that I did not understand including the many exclusions i.e. lines taken out plus points you have mentioned.

With regards gmcc point about slow progress for moving to 'Active, not recruiting' suggests the project is behind however Summit have not changed their deadlines so maybe the centres involved are still to update their progress.

For me with no real news at the moment the share price remaining steady is good enough for the present time.

[waterloo01] 23/2/2017 20:30

Key difference, I think, is that they are saying it's 'exported from the US'. Trump protection I suspect and no bad idea.

Also reference to 'no masking' . Freedosh might know what that means.

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment

[chrisatrdg] 23/2/2017 18:54

Per gmcc this evening posted on the other board:

'FYI : " PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD (PhaseOut DMD) "

Update 22nd Feb 2017 : Some changes made not very significant . Bit disappointing : Note still only two sites “Active, not recruiting " Remainder still shown as recruiting or Enrolling by invitation " ????



'

[chrisatrdg] 23/2/2017 18:44

Following football's posting another piece of good news is that currently the NASDAQ has clearly broken the $12 mark & is currently $12.28 (UK £1.96)there is now a marked lead by NASDAQ over AIM.Hopefully the late Buy of 10,000 shares today, on AIM, at full price may push the share price up on AIM Friday.

Edit:
Final close: $12.09 (UK £1.93) so $12 mark still exceeded looking forward to Friday.

NB: Used $1.25 to £.

[football] 23/2/2017 16:03

University of Oxford increases its stake in Summit Therapeutics
Share

15:02 23 Feb 2017

The world-renowned university has snapped up 50,000 shares in the drug discoverer

The University of Oxford has snapped up 50,000 shares in the AIM and Nasdaq-listed drug discoverer Summit Therapeutics PLC (LON:SUMM; NASDAQ:SUMM).

The uni exercised the warrants at 20p each; significantly lower than the 188p quoted in London on Thursday.

The two parties have been working together for a number of years to try and accelerate the development of future generation utrophin modulators for the treatment of the progressive muscle wasting disorder, Duchenne muscular dystrophy.

As part of that strategic alliance which was agreed back in 2013, the University was issued with a number of shares of warrants.

Shares in Summit dipped slightly to 188.6p in London.

[waterloo01] 22/2/2017 20:04

So I find although somewhat distracting.

[hugus maximus] 22/2/2017 19:58

Sitting around in anticipation of news does inspire a little creativity!

[waterloo01] 22/2/2017 16:01

Very cynical IMO and unlikely to be connected... but then again, I guess that's part of the purpose of having a vesting price, and given the last AGM vote, it seems unlikely they will reissue them if they lapse?

[hugus maximus] 22/2/2017 15:49

Nice to see the NASAQ nestling up around $12 again.

Conspiracy theorist's are suggesting on the other channel, that there's a good news flow due here in March, in order to consolidate a £2 plus share price for 60 days ... as the board's 2012 Share options are up!

I'm happy to ensure Glyn's got some pocket money if March/April indeed sees good data (FDX C Diff comparison results due & nudging toward Q2 for initial DMD news?)

GLA HM

[freemoney1] 21/2/2017 14:52

I guess each PI has their own buy out price but I don't think we are anywhere near that for most at the market price right now. Certainly not me :-)
Add a couple of zero's and I'd come to the table :-)

I would even think by the end of 2019 we could be looking at buying Sarepta to get our EU rights back!

[waterloo01] 21/2/2017 14:38

Last time SRPT came into money they did the deal with us. Apart from the milestone due, might they acquire more territory rights or even make a bid? Probably unlikely and unless it was at a significant premium, I'm sure it would be rebuffed, but as last time, these things can happen rather quickly. Just a thought!

[waterloo01] 21/2/2017 13:40

Even the FDA don't like them but they are in-place to encourage work in areas of rare diseases.

[hugus maximus] 21/2/2017 13:28

Folk also saying that with Trump suggesting he'll change the way these things work, it may ultimately have little value ... but I agree Solomon, the principle seems nuts!

[solomon] 21/2/2017 13:21

I don't understand why these Priority Review Vouchers are transferable. Surely they are meant to encourage the company that receives the voucher to be motivated in the field where they are having success, not to be passed on to some other company that might not have the qualification to use it properly.

[waterloo01] 21/2/2017 12:48

We've got one of these! (Lowest price paid in a while but still rather valuable)